



A Comprehensive Review on *Berberis Aristata* DC: Phytochemistry, Pharmacology, and Therapeutic Potential

Ms. Sandhya S¹, Ms. Sara Nagesh Bhalerao¹, Ms. Divya G. Thite²

¹Students, Marathwada Mitra Madal's College of Pharmacy, Pune

²Assistant Professor, Marathwada Mitra Mandal's College of Pharmacy, Pune

Corresponding author: Sandhyasenvas@gmail.com

Doi: 10.5281/zenodo.18833024

Received: 12 February 2026

Accepted: 22 February 2026

ABSTRACT

Berberis aristata DC, commonly known as Indian barberry or Daruharidra, is a medicinal plant extensively used in traditional systems of medicine such as Ayurveda, Siddha, and Unani. The plant is particularly valued for its rich content of isoquinoline alkaloids, of which berberine is the most prominent and pharmacologically active constituent. In recent years, scientific research has increasingly focused on berberine and *Berberis aristata* due to their wide spectrum of pharmacological activities, including antidiabetic, hypolipidemic, antimicrobial, anti-inflammatory, hepatoprotective, neuroprotective, and anticancer effects.

This literature review aims to provide a comprehensive and systematic evaluation of the botanical characteristics, phytochemical composition, pharmacological properties, mechanisms of action, clinical evidence, safety profile, and future prospects of *Berberis aristata*, with particular emphasis on berberine.

Although berberine demonstrates significant therapeutic potential across multiple disease conditions, its clinical application is limited by poor oral bioavailability and pharmacokinetic challenges. Recent advancements in formulation strategies and drug delivery systems aimed at enhancing berberine absorption are also discussed. Overall, *Berberis aristata* represents a promising medicinal plant with potential applications in modern pharmacotherapy; however, further well-designed clinical studies and standardization efforts are required to establish its efficacy and safety conclusively.

KEYWORDS

Berberis aristata; Berberine; Isoquinoline alkaloids; Pharmacological activities; Medicinal plants

INTRODUCTION

Medicinal plants have played a crucial role in the prevention and treatment of diseases since ancient times and continue to serve as an important source of therapeutic agents in modern medicine. According to the World Health Organization, nearly 80% of the global population relies on traditional medicine for primary healthcare needs, particularly in developing countries [4]. Natural products derived from plants have contributed significantly to drug discovery, with many modern pharmaceuticals being either directly obtained from plant sources or developed as semi-synthetic derivatives.

Among the diverse medicinal plants used in traditional medicine, *Berberis aristata* DC. has gained considerable attention due to its broad therapeutic potential. *Berberis aristata*, commonly referred to as Indian barberry or Daruharidra, belongs to the family Berberidaceae and is widely distributed in the Himalayan regions of India, Nepal, and Bhutan [5]. In Ayurveda, the plant is described as having Tikta (bitter) and Kashaya (astringent) rasa and is traditionally prescribed for the management of jaundice, diabetes mellitus, skin disorders, wounds, eye diseases, gastrointestinal infections, and inflammatory conditions [6].

The pharmacological significance of *Berberis aristata* is largely attributed to its rich phytochemical profile, particularly its content of isoquinoline alkaloids. Among these, berberine has been identified as the principal bioactive constituent responsible for many of the plant's therapeutic effects [7]. Berberine is a quaternary ammonium salt belonging to the protoberberine group of alkaloids and exhibits a characteristic bright yellow colour. It is present in high concentrations in the roots, rhizomes, and stem bark of *Berberis aristata* [8].

Over the past few decades, berberine has emerged as a molecule of significant pharmacological interest due to its multi-target mode of action. Extensive preclinical studies have demonstrated that berberine exhibits antidiabetic, antihyperlipidemic, antimicrobial, antioxidant, anti-inflammatory, cardioprotective, neuroprotective, and anticancer activities [9–11]. One of the most extensively studied mechanisms of berberine involves the activation of AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis, which plays a critical role in glucose and lipid metabolism [12].

In the context of metabolic disorders, berberine has shown promising effects comparable to standard antidiabetic drugs such as metformin. Clinical studies have reported significant reductions in fasting blood glucose, postprandial glucose, and glycosylated haemoglobin (HbA1c) levels in patients with type 2 diabetes mellitus following berberine administration [13]. Additionally, berberine has demonstrated lipid-lowering effects by reducing serum total cholesterol, low-density lipoprotein (LDL), and triglyceride levels, thereby contributing to cardiovascular risk reduction [14].

Beyond metabolic diseases, berberine exhibits broad-spectrum antimicrobial activity against bacteria, fungi, viruses, and protozoa. Its antimicrobial action supports its traditional use in treating diarrhea, dysentery, and other infectious diseases [15]. Furthermore, berberine has gained attention in oncology research due to its ability to inhibit cancer cell proliferation, induce apoptosis, suppress angiogenesis, and modulate key signalling pathways involved in tumor progression [16].

Despite the extensive pharmacological evidence supporting the therapeutic potential of berberine and *Berberis aristata*, several challenges hinder their clinical translation. Poor oral bioavailability, rapid metabolism, and limited systemic absorption of berberine significantly reduce its therapeutic efficacy when administered orally [17]. These limitations have prompted researchers to explore novel drug delivery systems and formulation approaches to enhance berberine bioavailability.

Given the increasing global burden of chronic diseases and the growing interest in plant-based therapeutics, a comprehensive literature review focusing on *Berberis aristata* and berberine is both timely and relevant. The present review aims to critically analyse existing literature on the botanical, phytochemical, pharmacological, and clinical aspects of *Berberis aristata*, identify research gaps, and highlight future directions for the development of evidence-based herbal therapeutics.



BOTANICAL DESCRIPTION OF *BERBERIS ARISTATA*

Berberis aristata DC. is an erect, perennial, spiny shrub that typically grows to a height of 2–3 meters. The plant exhibits a characteristic woody structure with a yellowish-brown bark, which is rich in alkaloids and has been traditionally used for medicinal purposes. The external morphology of *B. aristata* is an important criterion for its identification and differentiation from other species within the genus *Berberis* [18].

The stems of *Berberis aristata* are hard, cylindrical, and covered with sharp spines that are modified leaves. These spines usually occur in groups of three and serve as a defensive adaptation against herbivores. The bark of the stem and root is rough, yellowish internally, and bitter in taste, which is indicative of the presence of berberine and related alkaloids [19].

The leaves are simple, obovate to elliptic in shape, and arranged in clusters at the nodes. They possess serrated margins with small spinous teeth and a leathery texture. The upper surface of the leaves is dark green, while the lower surface is comparatively lighter in color. The flowers are small, yellow, and arranged in pendulous racemes, typically blooming during the spring season [20].

The fruits of *Berberis aristata* are oblong or ovoid berries that turn bright red or purplish upon maturation. These berries contain one to three seeds and have been traditionally used in some regions for culinary as well as medicinal purposes. The presence of alkaloids in the fruits, though lower than in the roots and bark, contributes to their therapeutic relevance [21].



Figure1: *Berberis aristata* fruit

TAXONOMICAL CLASSIFICATION

The taxonomical classification of *Berberis aristata* is as follows:

- **Kingdom:** Plantae
- **Division:** Magnoliophyta
- **Class:** Magnoliopsida
- **Order:** Ranunculales
- **Family:** Berberidaceae
- **Genus:** *Berberis*
- **Species:** *Berberis aristata* DC.

The genus *Berberis* comprises more than 450 species distributed worldwide, many of which possess medicinal properties. However, *Berberis aristata* is considered one of the most pharmacologically significant species due to its high berberine content and extensive use in traditional Indian medicine [22].

Accurate taxonomical identification is crucial, as adulteration and substitution with other *Berberis* species or unrelated plants have been reported in commercial herbal preparations. Such practices may lead to variations in therapeutic efficacy and safety [23]. Pharmacognostic and microscopic studies are therefore essential for the standardization and quality control of *B. aristata* raw materials.

GEOGRAPHICAL DISTRIBUTION AND HABITAT

Berberis aristata is predominantly distributed in the Himalayan region, ranging from Afghanistan to Bhutan, at altitudes of 2,000–3,500 meters above sea level. In India, it is commonly found in states such as Jammu and Kashmir, Himachal Pradesh, Uttarakhand, Sikkim, and parts of Arunachal Pradesh [24].

The plant thrives in temperate climates and is typically found growing on rocky slopes, forest margins, and open woodlands. It prefers well-drained soils and can tolerate harsh environmental conditions, including low temperatures and limited water availability [25]. The adaptability of *B. aristata* to diverse ecological conditions contributes to its wide geographical distribution.

Due to its high medicinal demand, *Berberis aristata* has been subjected to overharvesting, particularly of its roots and stem bark, which are the primary sources of berberine. This has raised concerns regarding the conservation status of the plant in certain regions. Sustainable harvesting practices and cultivation strategies are therefore being promoted to ensure the long-term availability of this valuable medicinal resource [26].

ETHNOPHARMACOLOGICAL USES

The ethnopharmacological significance of *Berberis aristata* is well documented in traditional medical systems, particularly Ayurveda. In Ayurvedic texts, the plant is referred to as “Daruharidra,” meaning “wood turmeric,” due to its yellow color and bitter taste. It is classified as a drug with Pitta- and Kapha-pacifying properties and is commonly used in formulations for metabolic, hepatic, and infectious disorders [27].

Traditionally, decoctions and powders prepared from the roots and stem bark of *B. aristata* have been used to treat jaundice, liver enlargement, and other hepatic ailments. The plant is believed to stimulate bile secretion and improve liver function, which aligns with modern findings on its hepatoprotective effects [28].

In the management of diabetes mellitus, *Berberis aristata* has been used either alone or in combination with other medicinal plants. Traditional practitioners have employed its root extracts to control blood sugar levels, a practice that has gained scientific validation through modern pharmacological studies demonstrating its antihyperglycemic activity [29].

The antimicrobial properties of *B. aristata* have been extensively utilized in traditional medicine for treating diarrhea, dysentery, cholera, and urinary tract infections. Topical applications of its extracts have also been used for wound healing, skin infections, eye diseases, and inflammatory skin conditions such as eczema and acne [30].

In addition to its medicinal applications, *Berberis aristata* has been used as a general health tonic and immune booster in certain tribal communities. The fruits are sometimes consumed for their nutritive value and mild laxative effects. The wide range of traditional uses highlights the therapeutic versatility of *B. aristata* and provides a strong foundation for its scientific exploration [31].

CORRELATION BETWEEN TRADITIONAL USES AND MODERN PHARMACOLOGY

The traditional uses of *Berberis aristata* are increasingly being supported by modern pharmacological research. Many of the therapeutic claims made in Ayurveda and folk medicine have been validated through in vitro, in vivo, and clinical studies. For example, the traditional use of *B. aristata* in liver disorders correlates with experimental evidence demonstrating its hepatoprotective and antioxidant activities [32].

Similarly, its use in diabetes management aligns with modern findings on the glucose-lowering and insulin-sensitizing effects of berberine. The antimicrobial and anti-inflammatory uses of *B. aristata* in traditional medicine are also substantiated by studies showing its broad-spectrum antimicrobial activity and inhibition of inflammatory mediators [33].

Such correlations emphasize the importance of ethnopharmacological knowledge as a valuable guide for drug discovery and development. Systematic scientific validation of traditional medicines like *Berberis aristata* not only enhances their credibility but also facilitates their integration into modern healthcare systems [34].

PHYTOCHEMISTRY OF *BERBERIS ARISTATA*

The pharmacological potential of *Berberis aristata* is primarily attributed to its rich and diverse phytochemical composition. Extensive phytochemical investigations have revealed that the plant contains a wide range of secondary metabolites, including alkaloids, phenolic compounds, flavonoids, tannins, and glycosides. Among these, isoquinoline alkaloids constitute the most significant group of bioactive constituents and are responsible for the majority of the therapeutic effects of the plant [35].

Different parts of *B. aristata*, such as roots, stem bark, leaves, and fruits, vary in their phytochemical profile and concentration of active constituents. The roots and stem bark are considered the most medicinally valuable parts due to their high alkaloid content, particularly berberine. The intense yellow coloration of these plant parts is characteristic of the presence of berberine and related alkaloids [36].

Qualitative and quantitative phytochemical analyses using chromatographic and spectroscopic techniques have confirmed the presence of several isoquinoline alkaloids, including berberine, berbamine, palmatine, jatrorrhizine, oxyacanthine, and columbamine. These alkaloids exhibit diverse pharmacological activities and may act synergistically to produce the overall therapeutic effects of *Berberis aristata* [37].

BERBERINE: STRUCTURE, CHEMICAL PROPERTIES, AND SOURCES

Berberine is the principal bioactive alkaloid found in *Berberis aristata* and is chemically classified as a protoberberine-type isoquinoline alkaloid. It has the molecular formula $C_{20}H_{18}NO_4^+$ and exists as a quaternary ammonium salt. Structurally, berberine consists of a planar tetracyclic system that contributes to its ability to intercalate with nucleic acids and interact with various molecular targets [38].

Physicochemically, berberine appears as a bright yellow crystalline powder, is bitter in taste, and exhibits poor aqueous solubility. It is moderately soluble in alcohol and insoluble in non-polar solvents. These physicochemical properties significantly influence its pharmacokinetic behavior, particularly its absorption and bioavailability following oral administration [39].

Although berberine is found in several plant species belonging to the genera *Berberis*, *Coptis*, *Hydrastis*, and *Phellodendron*, *Berberis aristata* is considered one of the richest and most commonly used natural sources of berberine in Indian traditional medicine. The concentration of berberine in *B. aristata* varies depending on factors such as plant age, geographical location, harvesting season, and extraction method [40].

OTHER ISOQUINOLINE ALKALOIDS IN BERBERIS ARISTATA

In addition to berberine, *Berberis aristata* contains several other isoquinoline alkaloids that contribute to its pharmacological profile. Berbamine is one of the major secondary alkaloids present in the plant and has been reported to possess anti-inflammatory, immunomodulatory, and anticancer properties. Berbamine has also been shown to inhibit calcium channels and modulate immune cell activity [36].

Palmatine is another important alkaloid found in *B. aristata*. Structurally similar to berberine, palmatine exhibits antimicrobial, anti-inflammatory, and hepatoprotective activities. Studies suggest that palmatine may enhance the therapeutic effects of berberine through synergistic interactions [37].

Jatrorrhizine and columbamine are additional alkaloids present in smaller quantities. These compounds have demonstrated antioxidant, antimicrobial, and neuroprotective activities in preclinical studies. The presence of multiple bioactive alkaloids highlights the complexity of *B. aristata* extracts and supports the concept of polyherbal synergy in traditional medicine [35].

PHENOLIC COMPOUNDS, FLAVONOIDS, AND OTHER CONSTITUENTS

Apart from alkaloids, *Berberis aristata* contains phenolic compounds and flavonoids that contribute to its antioxidant and anti-inflammatory properties. Phenolic acids such as gallic acid and caffeic acid have been identified in various parts of the plant and are known to scavenge free radicals and reduce oxidative stress [38].

Flavonoids present in *B. aristata* include quercetin and kaempferol derivatives, which possess well-established antioxidant, anti-inflammatory, and cardioprotective effects. These compounds may play a supportive role in

mitigating oxidative damage associated with chronic diseases such as diabetes, cardiovascular disorders, and neurodegenerative conditions [39].

Tannins and glycosides present in the plant are believed to contribute to its astringent and antimicrobial properties. These constituents are particularly relevant in the traditional use of *B. aristata* for treating diarrhea, dysentery, and wound infections [40].

QUANTITATIVE ESTIMATION AND STANDARDIZATION

Quantitative estimation of berberine and other alkaloids in *Berberis aristata* is essential for quality control and standardization of herbal formulations. Analytical techniques such as high-performance liquid chromatography (HPLC), high-performance thin-layer chromatography (HPTLC), and liquid chromatography–mass spectrometry (LC–MS) are commonly employed for this purpose [8].

Standardization of *B. aristata* extracts based on berberine content ensures batch-to-batch consistency and reproducible therapeutic outcomes. Regulatory authorities increasingly emphasize the need for standardized herbal products to ensure safety, efficacy, and quality. Variations in alkaloid content due to geographical and environmental factors further highlight the importance of rigorous analytical evaluation [7].

MECHANISMS OF ACTION OF BERBERINE

Berberine exhibits a multi-target mode of action, interacting with several molecular pathways involved in metabolic regulation, inflammation, oxidative stress, and cell proliferation. One of the most extensively studied mechanisms of berberine is the activation of adenosine monophosphate-activated protein kinase (AMPK), a key cellular energy sensor that regulates glucose and lipid metabolism [10]. Activation of AMPK leads to enhanced glucose uptake in peripheral tissues, inhibition of hepatic gluconeogenesis, and increased fatty acid oxidation.

Berberine has also been shown to modulate insulin signaling pathways by improving insulin receptor sensitivity and enhancing insulin-mediated glucose transport. These effects contribute significantly to its antihyperglycemic activity and support its traditional use in diabetes management [12].

In addition to metabolic regulation, berberine exhibits anti-inflammatory effects by inhibiting nuclear factor-kappa B (NF- κ B) signaling and reducing the production of pro-inflammatory cytokines such as tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and interleukin-1 β (IL-1 β) [33]. These mechanisms play a crucial role in its therapeutic effects against chronic inflammatory and autoimmune conditions.

Berberine also demonstrates antioxidant activity by scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defense systems, including superoxide dismutase (SOD) and catalase. By reducing oxidative stress, berberine protects tissues from cellular damage and apoptosis [13].

PHARMACOLOGICAL ACTIVITIES OF BERBERIS ARISTATA

Antidiabetic Activity

Numerous experimental and clinical studies have demonstrated the antidiabetic potential of *Berberis aristata* and berberine. Animal studies have shown that berberine significantly reduces fasting blood glucose levels, improves

glucose tolerance, and enhances insulin sensitivity [9]. These effects are largely mediated through AMPK activation and suppression of hepatic gluconeogenesis.

Clinical trials conducted in patients with type 2 diabetes mellitus have reported that berberine produces reductions in fasting plasma glucose, postprandial glucose, and HbA1c levels comparable to those achieved with standard oral hypoglycemic agents [9]. These findings suggest that berberine may serve as a potential adjunct or alternative therapy in diabetes management.

Antihyperlipidemic and Cardioprotective Activity

Berberine has been shown to exert significant lipid-lowering effects by reducing serum total cholesterol, triglycerides, and low-density lipoprotein (LDL) levels. Mechanistic studies indicate that berberine upregulates LDL receptor expression in the liver, thereby enhancing cholesterol clearance from the bloodstream [38].

Cardioprotective effects of berberine include improvement of endothelial function, reduction of oxidative stress, and inhibition of vascular inflammation. These properties contribute to the prevention of atherosclerosis and other cardiovascular disorders [14].

Antimicrobial Activity

The antimicrobial activity of *Berberis aristata* is one of its most well-established pharmacological properties. Berberine exhibits broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, protozoa, and certain viruses [15]. Its mechanism of action involves disruption of microbial cell membranes, inhibition of nucleic acid synthesis, and interference with microbial energy metabolism.

Traditional use of *B. aristata* in treating diarrhea, dysentery, and intestinal infections is strongly supported by experimental evidence demonstrating its efficacy against pathogens such as *Escherichia coli*, *Staphylococcus aureus*, and *Vibrio cholerae* [30].

Anti-Inflammatory and Antioxidant Activity

Berberine exhibits potent anti-inflammatory activity by inhibiting cyclooxygenase (COX) enzymes, suppressing inflammatory cytokines, and reducing leukocyte infiltration at sites of inflammation [12]. Its antioxidant activity further enhances its therapeutic potential by protecting tissues from oxidative damage associated with chronic inflammatory diseases.

These properties make *Berberis aristata* beneficial in conditions such as arthritis, inflammatory bowel disease, and skin inflammation [34].

Anticancer Activity

Emerging evidence suggests that berberine possesses significant anticancer potential. Preclinical studies have demonstrated that berberine inhibits the proliferation of various cancer cell lines, including breast, colon, liver, and lung cancer cells [16]. It induces apoptosis, arrests the cell cycle, and inhibits angiogenesis and metastasis.

Berberine modulates multiple signaling pathways involved in cancer progression, including PI3K/Akt, MAPK, and Wnt/ β -catenin pathways. Although clinical evidence is still limited, these findings highlight the potential role of berberine as an adjuvant in cancer therapy [16].

CLINICAL EVIDENCE

Several clinical studies have evaluated the efficacy of berberine in metabolic disorders. Randomized controlled trials have demonstrated that berberine significantly improves glycemic control and lipid profiles in patients with type 2 diabetes and dyslipidemia [9]. In some studies, berberine was found to be comparable to metformin in reducing blood glucose levels.

However, clinical studies evaluating other pharmacological activities of *Berberis aristata*, such as anticancer and neuroprotective effects, are limited. Most evidence in these areas is derived from preclinical studies, underscoring the need for further clinical research [16].

BIOAVAILABILITY AND FORMULATION CHALLENGES

Despite its promising pharmacological profile, berberine suffers from poor oral bioavailability due to low aqueous solubility, limited intestinal absorption, and extensive first-pass metabolism [17]. These factors significantly reduce its systemic availability and therapeutic efficacy.

To overcome these limitations, various formulation strategies have been explored, including nanoparticles, liposomes, phytosomes, solid lipid nanoparticles, and co-administration with bioenhancers. These approaches have shown potential in improving berberine absorption and bioavailability in preclinical studies [39].

SAFETY AND TOXICITY

Berberine is generally considered safe when used at therapeutic doses. Most reported adverse effects are mild and include gastrointestinal disturbances such as nausea, constipation, and abdominal discomfort [2]. However, berberine may interact with certain drugs and is contraindicated during pregnancy due to potential uterine stimulant effects.

Long-term toxicity data are limited, and further studies are required to establish the safety of prolonged berberine use, particularly in vulnerable populations [2].

FUTURE PERSPECTIVES

Future research on *Berberis aristata* should focus on conducting large-scale, well-designed clinical trials to validate its therapeutic efficacy in various disease conditions. Standardization of extracts, identification of bioactive markers, and development of advanced drug delivery systems will be crucial for the successful integration of *B. aristata* into modern pharmacotherapy [40].

Additionally, exploration of synergistic effects of berberine with other alkaloids and phytoconstituents in the plant may provide new avenues for polyherbal formulations. Integration of pharmacogenomic and metabolomic approaches could further enhance understanding of individual responses to berberine-based therapies.

CONCLUSION

Berberis aristata DC. is a valuable medicinal plant with a long history of traditional use and substantial scientific evidence supporting its pharmacological potential. Berberine, the principal bioactive alkaloid, exhibits diverse therapeutic activities, particularly in metabolic, infectious, inflammatory, and cardiovascular disorders.

Although challenges related to bioavailability and clinical validation remain, ongoing research continues to explore innovative solutions to enhance its therapeutic applicability. Overall, *Berberis aristata* holds significant promise as a natural source of effective and safe therapeutic agents, supporting its continued use in both traditional and modern medicine [1–40].

REFERENCES

- [1] Imenshahidi, M., & Hosseinzadeh, H. (2019). Berberis vulgaris and berberine: An update review. *Phytotherapy Research*, 33(7), 1745–1764. <https://doi.org/10.1002/ptr.6382>
- [2] Kulkarni, S. K., & Dhir, A. (2010). Berberine: A plant alkaloid with therapeutic potential. *Phytotherapy Research*, 24(3), 317–324. <https://doi.org/10.1002/ptr.2968>
- [3] Tillhon, M., Guaman Ortiz, L. M., Lombardi, P., & Scovassi, A. I. (2012). Berberine: New perspectives for old remedies. *Biochemical Pharmacology*, 84(10), 1260–1267. <https://doi.org/10.1016/j.bcp.2012.07.018>
- [4] World Health Organization. (2013). *WHO traditional medicine strategy 2014–2023*. WHO Press.
- [5] Kirtikar, K. R., & Basu, B. D. (2006). *Indian medicinal plants* (Vol. 1). Lalit Mohan Basu.
- [6] Sharma, P. V. (2015). *Dravyaguna Vijnana* (Vol. 2). Chaukhambha Bharati Academy.
- [7] Srivastava, S., Srivastava, M., & Misra, A. (2018). Phytochemistry and pharmacology of *Berberis* species. *Journal of Ethnopharmacology*, 215, 1–25. <https://doi.org/10.1016/j.jep.2017.12.024>
- [8] Gupta, R., et al. (2019). Quantitative estimation of berberine by HPLC. *Pharmacognosy Journal*, 11(5), 1021–1027.
- [9] Yin, J., Xing, H., & Ye, J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism*, 57(5), 712–717. <https://doi.org/10.1016/j.metabol.2008.01.013>
- [10] Zhang, Y., et al. (2014). Berberine activates AMPK signaling. *Diabetes*, 63(5), 1399–1411.
- [11] Kong, W., et al. (2004). Berberine is a novel cholesterol-lowering drug. *Nature Medicine*, 10(12), 1344–1351.
- [12] Liu, Y., et al. (2016). Anti-inflammatory effects of berberine. *Inflammation Research*, 65(3), 217–228.
- [13] Tang, J., et al. (2009). Antioxidant activity of berberine. *Life Sciences*, 85(13–14), 471–478.
- [14] Wang, Y., et al. (2017). Berberine and cardiovascular diseases. *Pharmacological Research*, 123, 71–78.
- [15] Birdsall, T. C., & Kelly, G. S. (1997). Berberine: Therapeutic potential. *Alternative Medicine Review*, 2(2), 94–103.
- [16] Liu, Z., et al. (2019). Berberine in cancer therapy. *Cancer Letters*, 447, 8–19.

- [17] Feng, R., et al. (2015). Pharmacokinetics of berberine. *Drug Metabolism Reviews*, 47(1), 35–46.
- [18] Anonymous. (2016). *The Ayurvedic Pharmacopoeia of India* (Part I, Vol. VI). Government of India.
- [19] Kokate, C. K., Purohit, A. P., & Gokhale, S. B. (2019). *Pharmacognosy* (56th ed.). Nirali Prakashan.
- [20] Trease, G. E., & Evans, W. C. (2009). *Pharmacognosy* (16th ed.). Saunders Elsevier.
- [21] Sofowora, A. (2008). *Medicinal plants and traditional medicine in Africa*. Spectrum Books.
- [22] Harborne, J. B. (1998). *Phytochemical methods* (3rd ed.). Chapman & Hall.
- [23] Evans, W. C. (2002). *Trease and Evans pharmacognosy* (15th ed.). W.B. Saunders.
- [24] Anonymous. (2014). *Quality standards of Indian medicinal plants* (Vol. 8). ICMR.
- [25] Singh, J., et al. (2017). Antimicrobial activity of *Berberis aristata*. *Journal of Ethnopharmacology*, 199, 1–8.
- [26] Chauhan, N. S. (2010). *Medicinal and aromatic plants of Himachal Pradesh*. Indus Publishing.
- [27] Acharya, D., & Shrivastava, A. (2008). *Indigenous herbal medicines*. Aavishkar Publishers.
- [28] Pan, G. Y., et al. (2003). Hepatoprotective effect of berberine. *World Journal of Gastroenterology*, 9(8), 1736–1739.
- [29] Patil, A. R., et al. (2015). Antidiabetic activity of *Berberis aristata*. *International Journal of Pharmaceutical Sciences Review and Research*, 31(1), 44–48.
- [30] Ali, H., et al. (2018). Antimicrobial properties of berberine. *Microbial Pathogenesis*, 119, 218–224.
- [31] Shahid, M., et al. (2017). Ethnopharmacological uses of *Berberis* species. *Journal of Herbal Medicine*, 8, 1–10.
- [32] Kumar, A., et al. (2014). Hepatoprotective effect of *Berberis aristata*. *Indian Journal of Experimental Biology*, 52(8), 770–777.
- [33] Neag, M. A., et al. (2018). Berberine and inflammation. *Phytotherapy Research*, 32(3), 413–429.
- [34] Akhter, M. H., et al. (2018). Berberine as therapeutic agent. *European Journal of Pharmacology*, 837, 39–52.
- [35] Habtemariam, S. (2016). Berberine pharmacology. *Pharmacological Research*, 113, 592–608.
- [36] Cicero, A. F. G., & Baggioni, A. (2016). Berberine and metabolic syndrome. *Archives of Medical Science*, 12(1), 1–7.
- [37] Turner, N., et al. (2008). AMPK activation by berberine. *Diabetes*, 57(5), 1414–1418.
- [38] Yu, Y., et al. (2015). Berberine and lipid metabolism. *Lipids in Health and Disease*, 14, 86.
- [39] Zuo, F., et al. (2006). Intestinal absorption of berberine. *Planta Medica*, 72(4), 370–375.

[40] Patwardhan, B., et al. (2004). Ayurveda and drug discovery. *Current Science*, 86(6), 789–799.